$HRGN
Harvard Apparatus Regenerative Technology Inc Stock $hrgn

$hrgn Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224011784 Filed on March 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$57.00K	$63.00K	$103.0K
YoY Change
Cost Of Revenue	$12.00K	$11.00K	$24.00K
YoY Change
Gross Profit	$45.00K	$52.00K	$79.00K
YoY Change
Gross Profit Margin	78.95%	82.54%	76.7%
Selling, General & Admin	$1.226M	$1.249M	$6.075M
YoY Change	-48.44%	62.63%	37.72%
% of Gross Profit	2724.44%	2401.92%	7689.87%
Research & Development	$840.0K	$631.0K	$2.994M
YoY Change	65.03%	-12.97%	71.87%
% of Gross Profit	1866.67%	1213.46%	3789.87%
Depreciation & Amortization	$6.000K	$6.000K	$35.00K
YoY Change	-50.0%	-50.0%	-32.69%
% of Gross Profit	13.33%	11.54%	44.3%
Operating Expenses	$2.078M	$1.880M	$9.069M
YoY Change	-28.02%	25.92%	47.39%
Operating Profit	-$2.021M	-$1.828M	-$8.990M
YoY Change	-30.0%		46.11%
Interest Expense		$64.00K	$64.00K
YoY Change			611.11%
% of Operating Profit
Other Income/Expense, Net	-$9.000K	-$62.00K	-$19.00K
YoY Change	200.0%	3000.0%	-123.75%
Pretax Income	-$2.030M	-$1.826M	-$8.945M
YoY Change	-29.76%	22.14%	47.29%
Income Tax
% Of Pretax Income
Net Earnings	-$2.030M	-$1.826M	-$9.022M
YoY Change	-29.76%	15.57%	48.56%
Net Earnings / Revenue	-3561.4%	-2898.41%	-8759.22%
Basic Earnings Per Share	-$0.15		-$0.67
Diluted Earnings Per Share	-$0.15	-$0.13	-$0.67
COMMON SHARES
Basic Shares Outstanding	13.95M shares	13.95M shares	13.46M shares
Diluted Shares Outstanding	13.95M shares		13.46M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$272.0K	$432.0K	$432.0K
YoY Change	-91.68%	-65.19%	-65.19%
Cash & Equivalents	$272.0K	$432.0K
Short-Term Investments
Other Short-Term Assets	$294.0K	$297.0K	$297.0K
YoY Change	-17.65%	482.35%	-15.86%
Inventory	$44.00K	$50.00K	$50.00K
Prepaid Expenses
Receivables	$7.000K	$4.000K	$4.000K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$617.0K	$783.0K	$783.0K
YoY Change	-82.98%	-50.88%	-50.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$19.00K	$73.00K	$73.00K
YoY Change	-58.7%	48.98%	-62.76%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.758M	$1.758M	$1.758M
YoY Change	223.16%	188.2%	188.2%
Total Long-Term Assets	$1.798M	$1.831M	$1.831M
YoY Change	153.24%	127.17%	127.17%
TOTAL ASSETS
Total Short-Term Assets	$617.0K	$783.0K	$783.0K
Total Long-Term Assets	$1.798M	$1.831M	$1.831M
Total Assets	$2.415M	$2.614M	$2.614M
YoY Change	-44.3%	8.92%	8.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$890.0K	$445.0K	$445.0K
YoY Change	17.88%	-34.75%	-34.75%
Accrued Expenses	$532.0K	$522.0K	$522.0K
YoY Change	-5.51%	-21.97%	-21.97%
Deferred Revenue
YoY Change
Short-Term Debt	$500.0K	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.240M	$968.0K	$968.0K
YoY Change	68.93%	-28.98%	-28.98%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.240M	$968.0K	$968.0K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.240M	$968.0K	$968.0K
YoY Change	66.3%	-31.4%	-31.4%
SHAREHOLDERS EQUITY
Retained Earnings	-$94.00M	-$92.00M
YoY Change	9.43%	10.84%
Common Stock	$139.0K	$139.0K
YoY Change	9.45%	13.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$175.0K	$1.646M	$1.646M
YoY Change
Total Liabilities & Shareholders Equity	$2.415M	$2.614M	$2.614M
YoY Change	-44.3%	8.92%	8.92%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$2.030M	-$1.826M	-$9.022M
YoY Change	-29.76%	15.57%	48.56%
Depreciation, Depletion And Amortization	$6.000K	$6.000K	$35.00K
YoY Change	-50.0%	-50.0%	-32.69%
Cash From Operating Activities	-$960.0K	-$1.218M	-$6.939M
YoY Change	-5.23%	-29.72%	35.9%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$11.00K
YoY Change		-100.0%	120.0%
Acquisitions
YoY Change
Other Investing Activities		$1.232M	$0.00
YoY Change
Cash From Investing Activities		$1.232M	-$11.00K
YoY Change		40966.67%	120.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$6.141M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$801.0K	149.0K	6.141M
YoY Change	-73.74%		21.36%
NET CHANGE
Cash From Operating Activities	-$960.0K	-1.218M	-6.939M
Cash From Investing Activities		1.232M	-11.00K
Cash From Financing Activities	$801.0K	149.0K	6.141M
Net Change In Cash	-$159.0K	163.0K	-809.0K
YoY Change	-107.84%	-109.42%	1486.27%
FREE CASH FLOW
Cash From Operating Activities	-$960.0K	-$1.218M	-$6.939M
Capital Expenditures		$0.00	$11.00K
Free Cash Flow	-$960.0K	-$1.218M	-$6.950M
YoY Change	-6.07%	-29.6%	35.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001563665
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2022Q4	us-gaap	Inventory Net InventoryNet		usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent		usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent		usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022	HRGN	Cost Of Sales CostOfSales		usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense		usd
CY2023	HRGN	Sublease Expense Income SubleaseExpenseIncome		usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022	us-gaap	Interest And Other Income InterestAndOtherIncome		usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2022	HRGN	Stock Issued During Period Value Convertible Preferred Stock StockIssuedDuringPeriodValueConvertiblePreferredStock		usd
CY2022	HRGN	Issuance Of Common Stock From Exercise Of Warrants IssuanceOfCommonStockFromExerciseOfWarrants		usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense		usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
CY2022	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023	HRGN	Settlement Of Contingency Matter SettlementOfContingencyMatter		usd
CY2023	HRGN	Settlement Amount Due To Parent Included In Accrued And Other Current Liabilities SettlementAmountDueToParentIncludedInAccruedAndOtherCurrentLiabilities		usd
CY2023	us-gaap	Stock Issued1 StockIssued1		usd
CY2023	HRGN	Increase Of Right Of Use Asset And Liability Due To Lease Extension IncreaseOfRightOfUseAssetAndLiabilityDueToLeaseExtension		usd
CY2023Q4	HRGN	Prepaid Deposits PrepaidDeposits		usd
CY2023Q4	HRGN	Accrued Legal Expenses Current AccruedLegalExpensesCurrent		usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue		usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2022Q2	HRGN	Fair Value Assumptions Warrants Expected Dividend Yield FairValueAssumptionsWarrantsExpectedDividendYield		pure
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-35853
CY2023	dei	Entity Registrant Name EntityRegistrantName	Harvard Apparatus Regenerative Technology, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-5210462
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	84 October Hill Road
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 11
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Holliston
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01746
CY2023	dei	City Area Code CityAreaCode	(774)
CY2023	dei	Local Phone Number LocalPhoneNumber	233-7300
CY2023	dei	Security12g Title Security12gTitle	Common Stock, $0.01 par value
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	33800000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13947324	shares
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, MA
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	432000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1241000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	50000	usd
CY2023Q4	HRGN	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	210000	usd
CY2022Q4	HRGN	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	274000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	87000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	79000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	783000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1594000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	49000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	48000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	147000	usd
CY2023Q4	HRGN	Deferred Financing Cost Non Current DeferredFinancingCostNonCurrent	544000	usd
CY2022Q4	HRGN	Deferred Financing Cost Non Current DeferredFinancingCostNonCurrent	610000	usd
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	1214000	usd
CY2023Q4	us-gaap	Assets Assets	2614000	usd
CY2022Q4	us-gaap	Assets Assets	2400000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	445000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	682000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	475000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	582000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	48000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	99000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	968000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1363000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	48000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	968000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1411000	usd
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000	shares
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	4180	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	4180	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	4180000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13947324	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13947324	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12174467	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12174467	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	139000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	122000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	93463000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	79698000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-91956000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-83011000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1646000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3191000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2614000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2400000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	103000	usd
CY2023	HRGN	Cost Of Sales CostOfSales	24000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3062000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1742000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	294000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5713000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4411000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	9093000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	6153000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-8990000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-6153000	usd
CY2022	HRGN	Sublease Expense Income SubleaseExpenseIncome	87000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2000	usd
CY2023	us-gaap	Interest And Other Income InterestAndOtherIncome	64000	usd
CY2023	us-gaap	Interest Expense InterestExpense	14000	usd
CY2022	us-gaap	Interest Expense InterestExpense	9000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	45000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	80000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8945000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6073000	usd
CY2023	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	77000	usd
CY2022	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	180000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9022000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6253000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.55
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-3029000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6073000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1031000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	-180000	usd
CY2022	HRGN	Issuance Of Common Stock And Warrants To Purchase Common Stock Value Net Of Offering Costs IssuanceOfCommonStockAndWarrantsToPurchaseCommonStockValueNetOfOfferingCosts	5060000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3191000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8945000	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	4257000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	-77000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5992000	usd
CY2023	HRGN	Stock Issued During Period Value Issuance Of Common Stock From Exercise Of Options StockIssuedDuringPeriodValueIssuanceOfCommonStockFromExerciseOfOptions	149000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1646000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8945000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6073000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	3461000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1031000	usd
CY2023	us-gaap	Depreciation Depreciation	35000	usd
CY2022	us-gaap	Depreciation Depreciation	52000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	99000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	22000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	50000	usd
CY2023	HRGN	Increase Decrease In Prepaid Research And Development IncreaseDecreaseInPrepaidResearchAndDevelopment	-64000	usd
CY2022	HRGN	Increase Decrease In Prepaid Research And Development IncreaseDecreaseInPrepaidResearchAndDevelopment	274000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-216000	usd
CY2023	HRGN	Increase Decrease In Deferred Financing Costs IncreaseDecreaseInDeferredFinancingCosts	-66000	usd
CY2022	HRGN	Increase Decrease In Deferred Financing Costs IncreaseDecreaseInDeferredFinancingCosts	610000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1214000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-237000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-99000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-22000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-107000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	548000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6939000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5106000	usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	2523000	usd
CY2023	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	2523000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5992000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5060000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	149000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6141000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5060000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-809000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-51000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1241000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1292000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	432000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1241000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	14000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	9000	usd
CY2022	HRGN	Settlement Of Contingency Matter SettlementOfContingencyMatter	-3250000	usd
CY2022	HRGN	Settlement Amount Due To Parent Included In Accrued And Other Current Liabilities SettlementAmountDueToParentIncludedInAccruedAndOtherCurrentLiabilities	-750000	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	4000000	usd
CY2023	us-gaap	Dividends Preferred Stock DividendsPreferredStock	77000	usd
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock	180000	usd
CY2022	HRGN	Increase Of Right Of Use Asset And Liability Due To Lease Extension IncreaseOfRightOfUseAssetAndLiabilityDueToLeaseExtension	63000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-92000000.0	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	400000	usd
CY2023	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	500000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_840_eus-gaap--UseOfEstimates_zkAWSxQ5Fgtc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_z0TGTUg9pdZf">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The process of preparing consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such estimates include, but are not limited to, share-based compensation, valuation of warrant liability, accrued expenses and the valuation allowance for deferred income taxes. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Payments For Deposits PaymentsForDeposits	1200000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	1200000	usd
CY2023	HRGN	Fair Value Transfers Between Level Hierarchies FairValueTransfersBetweenLevelHierarchies	0	usd
CY2022	HRGN	Fair Value Transfers Between Level Hierarchies FairValueTransfersBetweenLevelHierarchies	0	usd
CY2022	us-gaap	Depreciation Depreciation	52000	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023Q4	us-gaap	Translation Adjustment Functional To Reporting Currency Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax	1000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	49000	usd
CY2023	us-gaap	Depreciation Depreciation	35000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_z23j9FVJ3Ur6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_862_ztqN27iFsrf3">Concentration of Credit Risk</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial investments that potentially subject the Company to credit risk consist of cash. The Company has all cash at accredited financial institutions. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (FDIC) up to $<span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zYbNm6CkPPD3" title="Cash insured by FDIC">250,000</span>. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q4	HRGN	Prepaid Deposits PrepaidDeposits	20000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	8000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	8000	usd
CY2023Q4	HRGN	Prepaid Expense Contracts PrepaidExpenseContracts	79000	usd
CY2022Q4	HRGN	Prepaid Expense Contracts PrepaidExpenseContracts	51000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	87000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	79000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1487000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1476000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1462000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1427000	usd
CY2023	us-gaap	Payments For Deposits PaymentsForDeposits	1200000	usd
CY2023Q4	HRGN	Accrued Advisory Costs Current AccruedAdvisoryCostsCurrent	325000	usd
CY2022Q4	HRGN	Accrued Advisory Costs Current AccruedAdvisoryCostsCurrent	300000	usd
CY2022Q4	HRGN	Accrued Legal Expenses Current AccruedLegalExpensesCurrent	135000	usd
CY2023Q4	HRGN	Accrued Audit Services Current AccruedAuditServicesCurrent	70000	usd
CY2022Q4	HRGN	Accrued Audit Services Current AccruedAuditServicesCurrent	80000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	79000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	55000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	12000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	475000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	582000	usd
CY2017Q4	HRGN	Warrants To Be Remeasured Number WarrantsToBeRemeasuredNumber	1044396	shares
CY2017Q4	HRGN	Warrants To Be Modified Number WarrantsToBeModifiedNumber	952184	shares
CY2023Q4	HRGN	Warrants To Be Remeasured Number WarrantsToBeRemeasuredNumber	92212	shares
CY2022Q1	HRGN	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Expired SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsExpired	92212	shares
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	2000	usd
CY2023Q4	us-gaap	Loss Contingency Estimate Of Possible Loss LossContingencyEstimateOfPossibleLoss	5900000	usd
CY2023Q4	us-gaap	Loss Contingency Estimate Of Possible Loss LossContingencyEstimateOfPossibleLoss	5900000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	48000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	147000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	48000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	99000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	48000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	48000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	147000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	127000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	121000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y5M23D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y5M4D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1466	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1474	pure
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	23176000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	22972000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	127000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	121000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	50000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	50000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	48000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.063	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.063	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.006	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.008	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.279	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.281	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	19167000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20487000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1288000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1083000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2504000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1566000	usd
CY2023Q4	HRGN	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	13000	usd
CY2022Q4	HRGN	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	40000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22959000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	23136000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	13000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	40000	usd
CY2023Q4	HRGN	Deferred Tax Liability Operating Lease Assets DeferredTaxLiabilityOperatingLeaseAssets	13000	usd
CY2022Q4	HRGN	Deferred Tax Liability Operating Lease Assets DeferredTaxLiabilityOperatingLeaseAssets	40000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	13000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	40000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	200000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2900000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.80	pure
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	66000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	35000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	40961765	shares
CY2022Q2	HRGN	Fair Value Assumption Warrant Risk Free Interest Rate FairValueAssumptionWarrantRiskFreeInterestRate	0.0281	pure
CY2022Q2	HRGN	Fair Value Assumptions Warrants Expected Volatility Rates FairValueAssumptionsWarrantsExpectedVolatilityRates	1.2736	pure
CY2022Q2	HRGN	Fair Value Assumptions Warrants Expected Terms FairValueAssumptionsWarrantsExpectedTerms	P5Y
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.88
CY2022Q2	us-gaap	Share Price SharePrice	5.50
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2332603	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.93
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	294000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	334418	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.84
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	150097	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.39
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2516924	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.95
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M4D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6917000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2130007	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.81
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	65264	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.29
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	604378	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.13
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3977289	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.64
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y8M12D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5728000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2281655	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.64
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y2M26D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	4209000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3877871	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.69
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y8M12D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	5522000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0382	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0274	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.2535	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.2361	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.12
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.23
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8945000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6073000	usd
CY2023	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	77000	usd
CY2022	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	180000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9022000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6253000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13455666	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13455666	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11349610	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11349610	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.55
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5090911	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4249805	shares
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	103000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8945000	usd
CY2023Q4	us-gaap	Assets Assets	2614000	usd

Files In Submission

Name	View Source	Status
0001493152-24-011784-index-headers.html	Edgar Link	pending
0001493152-24-011784-index.html	Edgar Link	pending
0001493152-24-011784.txt	Edgar Link	pending
0001493152-24-011784-xbrl.zip	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
form10-k_003.jpg	Edgar Link	pending
form10-k_004.jpg	Edgar Link	pending
hrgn-20231231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
hrgn-20231231_def.xml	Edgar Link	unprocessable
hrgn-20231231_lab.xml	Edgar Link	unprocessable
hrgn-20231231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
hrgn-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HRGN
Harvard Apparatus Regenerative Technology Inc Stock $hrgn

2024 Q1 Form 10-K Financial Statement

#000149315224011784 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HRGN Harvard Apparatus Regenerative Technology Inc Stock $hrgn

2024 Q1 Form 10-K Financial Statement

#000149315224011784 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HRGN
Harvard Apparatus Regenerative Technology Inc Stock $hrgn